07.05.2021 SYNLAB AG  DE000A2TSL71

DGAP-News: Highlights from SYNLAB Germany | SYNLAB supports the German state of North Rhine-Westphalia with regular lollipop-PCR-tests for pupils at elementary and specialist schools


 

DGAP-News: SYNLAB AG / Key word(s): Product Launch/Alliance
Highlights from SYNLAB Germany | SYNLAB supports the German state of North Rhine-Westphalia with regular lollipop-PCR-tests for pupils at elementary and specialist schools

07.05.2021 / 12:00
The issuer is solely responsible for the content of this announcement.


SYNLAB Holding Germany GmbH
Gubener Straße 39
86156 Augsburg
Press release


Highlights from SYNLAB Germany | SYNLAB supports the German state of North Rhine-Westphalia with regular lollipop-PCR-tests for pupils at elementary and specialist schools

  • For the state of North Rhine-Westphalia (NRW), SYNLAB will regularly test pupils for SARS-CoV-2 using PCR-based lollipop tests
  • Simple and time-saving sampling in schools under the supervision of teachers enable safe schooling during pandemic
  • PCR-pooling-method ensures efficiency and high accuracy

SYNLAB, the largest European clinical laboratory and medical diagnostic services provider, together with other laboratories from NRW, will regularly provide screenings for pupils in North Rhine-Westphalia with the so-called lollipop-PCR-tests. Starting 10 May 2021, pupils at elementary and specialist schools will have the opportunity to do such a test twice a week. For this purpose, the individual samples will be analysed through the PCR-pooling-method. This set-up was agreed upon in a joint decision by the laboratories and the State Ministry for School and Education of North Rhine-Westphalia.

Due to the simple sample collection and the efficient and very accurate PCR-pooling-method, the lollipop-PCR-test is particularly well suited for use in schools. For sampling, pupils suck on a cotton swab for about 30 seconds. Then, up to 15 swabs are collected in a so-called pool tube. If there are more than 15 pupils in one class, additional swabs are collected in another pool tube. Thereafter, a logistics service picks up the samples directly at the schools and brings them straight to the laboratories for examination. Results are available the next morning.

The SYNLAB Access App provides school administrators, teachers and parents who are served by SYNLAB with a step-by-step guideline for the sampling procedure. If a pool tests positive, SYNLAB immediately informs the school's testing officer, who in turn informs affected pupils, parents, and responsible teachers. In such a case, all pupils who were part of the positive pool use a second, previously distributed cotton swab to take a sample at home for a so-called retest. This retest is a highly sensitive PCR-test as well and makes it possible to identify which individual samples are positive and which are negative.

Dr Martin Roskos, Chief Medical Officer of SYNLAB Germany, emphasises the added value of the new test method compared to conventional sampling methods: "Compared to nasopharyngeal swabs or the gargle test, sampling with lollipop-PCR-tests is very easy, even for small children. In addition, this sampling-procedure can be supervised by teachers in schools to save time for actual school lessons. Overall, with the lollipop-PCR-test we offer a solution that is specifically tailored to the young and very young generation."

Likewise, Dr Hassan Jomaa, medical director of the SYNLAB laboratory in Leverkusen, is convinced by the lollipop-PCR-tests and emphasises the state's pioneering role: "Introducing lollipop-PCR-testing in collaboration with the State Ministry for School and Education, we are establishing an effective testing concept for schools throughout NRW. The lollipop-PCR-test makes simple, regular, and accurate testing in schools possible. We are very pleased that our work in SYNLAB's Leverkusen laboratory will help protecting pupils and providing relieve for teachers and parents, all while strengthening safe schooling during the pandemic."

With a sensitivity of more than 90 per cent, the PCR-pooling-method used for lollipop-PCR-testing offers a significantly higher accuracy than rapid antigen tests. In fact, SYNLAB studies have shown that about 40 percent of asymptomatic people tested positive on SARS-CoV-2 are not detected by rapid antigen tests.
 

- End -

 

For more information:

Christian Ries,
SYNLAB Holding Germany GmbH
+49 821 52157-210
[email protected]
 


About the SYNLAB Group

  • SYNLAB Group is the largest European clinical laboratory and medical diagnostic services provider by revenue and number of tests. SYNLAB offers a full range of innovative and reliable medical diagnostics for patients, practising doctors, clinics and the pharmaceutical industry.
  • Providing the leading level of service within the industry, SYNLAB is the partner of choice for diagnostics in human and veterinary medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.
  • SYNLAB operates in 36 countries across four continents and holds leading positions in most markets. More than 20,000 employees (FTE), including over 1,200 medical experts, as well as a large number of other specialists such as biologists, chemists and laboratory technicians, contribute every day to the Group's worldwide success. SYNLAB carries out approximately 500 million laboratory tests per year and achieved Group revenues of EUR 2.6 billion in 2020.
  • More information can be found on www.synlab.com


07.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: SYNLAB AG
Moosacher Straße 88
80809 Munich
Germany
Phone: +49 1701183753
E-mail: [email protected]
Internet: www.synlab.com/
ISIN: DE000A2TSL71
WKN: A2TSL7
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1194017

 
End of News DGAP News Service

1194017  07.05.2021 

fncls.ssp?fn=show_t_gif&application_id=1194017&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 0,00 0,00 1.807,90 1.906,10 2.621,20 3.764,92 3.000,00
EBITDA1,2 0,00 0,00 382,90 397,40 679,20 1.179,89 722,00
EBITDA-Marge3 0,00 0,00 21,18 20,85 25,91 31,34 24,07
EBIT1,4 0,00 0,00 138,80 71,90 315,50 914,53 505,00
EBIT-Marge5 0,00 0,00 7,68 3,77 12,04 24,29 16,83
Jahresüberschuss1 0,00 0,00 -42,10 -108,00 259,10 627,54 278,00
Netto-Marge6 0,00 0,00 -2,33 -5,67 9,88 16,67 9,27
Cashflow1,7 0,00 0,00 120,30 238,60 904,70 1.011,70 0,00
Ergebnis je Aktie8 0,00 0,00 -0,19 -0,49 1,16 2,82 1,20
Dividende8 0,00 0,00 0,00 0,00 0,00 0,33 0,35
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Deloitte

INVESTOR-INFORMATIONEN
©boersengefluester.de
Synlab
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2TSL7 13,590 3.020,00
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
12,94 9,85 1,31 13,66
KBV KCV KUV EV/EBITDA
1,34 2,99 0,80 3,43
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,35 0,35 2,58 16.05.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
12.05.2022 11.08.2022 10.11.2022 16.03.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
4,68% -12,36% -42,42% -38,78%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu SYNLAB AG  ISIN: DE000A2TSL71 können Sie bei EQS abrufen


Medtech , A2TSL7 , SYAB , XETR:SYAB